167 related articles for article (PubMed ID: 7599563)
1. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.
Hertenstein B; Hampl W; Bunjes D; Wiesneth M; Duncker C; Koszinowski U; Heimpel H; Arnold R; Mertens T
Bone Marrow Transplant; 1995 Mar; 15(3):387-93. PubMed ID: 7599563
[TBL] [Abstract][Full Text] [Related]
2. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
3. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
5. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
8. The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation.
Würsch AM; Gratama JW; Middeldorp JM; Nissen C; Gratwohl A; Speck B; Jansen J; D'Amaro J; The TH; De Gast GC
Clin Exp Immunol; 1985 Nov; 62(2):278-87. PubMed ID: 3002684
[TBL] [Abstract][Full Text] [Related]
9. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
Ringdén O; Pihlstedt P; Markling L; Aschan J; Båryd I; Ljungman P; Lönnqvist B; Tollemar J; Janossy G; Sundberg B
Bone Marrow Transplant; 1991 Mar; 7(3):221-6. PubMed ID: 2059758
[TBL] [Abstract][Full Text] [Related]
10. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
[TBL] [Abstract][Full Text] [Related]
11. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
12. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies.
Couriel D; Canosa J; Engler H; Collins A; Dunbar C; Barrett AJ
Bone Marrow Transplant; 1996 Aug; 18(2):347-53. PubMed ID: 8864445
[TBL] [Abstract][Full Text] [Related]
13. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
[TBL] [Abstract][Full Text] [Related]
14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes.
Contassot E; Robinet E; Angonin R; Laithier V; Bittencourt M; Pavy JJ; Cahn JY; Hervé P; Tiberghien P
Bone Marrow Transplant; 1998 Dec; 22(11):1097-102. PubMed ID: 9877273
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
18. Interstitial pneumonitis in T cell-depleted bone marrow transplantation.
Breuer R; Or R; Lijovetzky G; Naparstek E; Engelhard D; Lafair J; Weshler Z; Slavin S
Bone Marrow Transplant; 1988 Nov; 3(6):625-30. PubMed ID: 2850831
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo depletion of T cells.
Arnold R; Bunjes D; Wiesneth M; Hertenstein B; Theobald M; Heimpel H; Hale G; Waldmann H
Bone Marrow Transplant; 1993; 12 Suppl 3():S11-2. PubMed ID: 8124250
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]